Mizuho Securities analyst Mara Goldstein maintained a Hold rating on TCR2 Therapeutics (TCRR – Research Report) today and set a price target of $2.11. The company’s shares closed yesterday at $1.98.
According to TipRanks, Goldstein is an analyst with an average return of -3.0% and a 35.08% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Merck & Company, Incyte, and Autolus Therapeutics.
TCR2 Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.53.
See Insiders’ Hot Stocks on TipRanks >>
TCRR market cap is currently $77.7M and has a P/E ratio of -0.50.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCRR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Read More on TCRR:
- TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alaunos Therapeutics appoints Hofmeister to board of directors
- TCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
